文献速递肝病

无干扰素方案改善晚期肝病HIV/HCV共感染患者的门静脉高压与组织学坏死性炎症

Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease.
PubMed 文献 · Aliment Pharmacol Ther · 2016-11-07

研究纳入22例成功获得持续病毒学应答(SVR)的HIV/HCV共感染且存在门静脉高压的患者,比较无干扰素方案治疗前后肝静脉压力梯度(HVPG)、肝组织学及血浆生物标志物的变化。结果显示HVPG总体下降,临床显著门静脉高压者73%出现血流动力学应答,肝硬度下降,50%肝硬化患者METAVIR分期改善,但39%患者仍存在持续性组织学坏死性炎症。

要点

  • HVPG从基线10.7±4.1 mmHg降至7.4±4.2 mmHg(Δ:-3.3±2.7 mmHg,p<0.001)。
  • 临床显著门静脉高压(HVPG≥10 mmHg)者HVPG从14.1±2.9降至10.4±3.9 mmHg,73%出现血流动力学应答。
  • 39%患者治疗后仍有持续性组织学坏死性炎症(METAVIR A1),与HVPG应答较差及脂肪变相关。

核心结论

  • 无干扰素治疗在多数HIV/HCV共感染患者获得SVR后降低门静脉高压并阻止组织学坏死性炎症活动,可能促进肝硬化肝功能再代偿。
  • 生物标志物或可识别持续性肝脏坏死性炎症的患者。

研究设计与样本

  • 纳入22例既往及成功无干扰素治疗(SVR)后均有配对肝静脉压力梯度(HVPG)测量的HIV/HCV共感染且存在门静脉高压的患者。
  • 肝硬度采用瞬时弹性成像评估,肝活检按METAVIR评分,血浆生物标志物采用ELISA测定。

主要发现

  • HVPG从基线10.7±4.1 mmHg降至治疗后7.4±4.2 mmHg(Δ:-3.3±2.7 mmHg,p<0.001)。
  • 临床显著门静脉高压(HVPG≥10 mmHg,n=11)患者HVPG从14.1±2.9降至10.4±3.9 mmHg(Δ:-3.7±3.3 mmHg,p=0.004),73%出现血流动力学应答(HVPG下降≥10%)。
  • 亚临床门静脉高压(HVPG 6-9 mmHg,n=11)患者中64%在SVR时门静脉压力正常化。
  • 平均肝硬度从20.8 kPa降至11.5 kPa(Δ:-8.8±7.4 kPa,p<0.001)。
  • 肝硬化患者中50%(7/14)重新分类为METAVIR≤F3,所有失代偿期肝硬化患者Child-Pugh分期改善。

关键数值与推荐

  • 临床显著门静脉高压定义为HVPG≥10 mmHg(n=11)。
  • 亚临床门静脉高压定义为HVPG 6-9 mmHg(n=11)。
  • 血流动力学应答定义为HVPG下降≥10%。
  • 治疗后39%患者仍有持续性组织学坏死性炎症活动(METAVIR A1),与HVPG应答较差及更多脂肪变相关。
  • METAVIR A1患者血浆纤维化(PDGF、TGF-β)和血管生成(VEGF、Angiopoietin1)生物标志物水平显著更高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HIV/HCV co-infected patients show accelerated fibrosis progression and higher risk for complications of portal hypertension (PHT). AIM: To assess the effects of interferon-free therapy on portal pressure, liver histology and plasma biomarkers in HIV/HCV-coinfected patients with PHT. METHODS: Twenty-two patients with paired hepatic venous pressure gradient (HVPG) measurements prior and after successful treatment (SVR) with interferon-free regimens were included. Liver stiffness was assessed by transient elastography and biopsies were scored according to METAVIR. Plasma biomarkers were determined by ELISA. RESULTS: Overall, HVPG decreased from 10.7 ± 4.1 mmHg at baseline to 7.4 ± 4.2 mmHg after HCV treatment (Δ:-3.3 ± 2.7 mmHg; p < 0.001). In patients with clinically significant PHT (HVPG≥10 mmHg, n = 11), HVPG decreased from 14.1 ± 2.9 to 10.4 ± 3.9 mmHg (Δ:-3.7 ± 3.3 mmHg; p = 0.004) and a haemodynamic response (HVPG decrease ≥10%) was observed in 73%. In 64% of patients with subclinical PHT (HVPG 6-9 mmHg, n = 11), portal pressure normalised at SVR. Mean liver stiffness decreased from 20.8 kPa to 11.5 kPa (Δ:-8.8 ± 7.4 kPa; p < 0.001). Fifty percent (7/14) of patients with cirrhosis were re-classified as METAVIR ≤F3 and all patients with decompensated cirrhosis improved their Child-Pugh stage. After successful HCV treatment, 39% still had persistent histological necroinflammatory activity (METAVIR A1), which correlated with less HVPG response and more steatosis. While most biomarkers improved with SVR, METAVIR A1 patients had significantly higher plasma levels of fibrogenic (PDGF, TGF-β) and angiogenic (VEGF, Angiopoietin1) biomarkers. CONCLUSIONS: Interferon-free therapy reduces PHT and halts histological necroinflammatory activity in the majority of HIV/HCV-coinfected patients after SVR, which may lead to re-compensation of liver function in cirrhosis. Biomarkers could identify patients with persisting hepatic necroinflammation.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Schwabl P, Mandorfer M, Steiner S, et al. Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. Aliment Pharmacol Ther. 2016. PMID: 27910154. doi:10.1111/apt.13844

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。